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Abstract
Background: Phenylketonuria (PKU) is a rare inborn error of metabolism often complicated by a progressive bone
impairment of uncertain etiology, as documented by both ionizing and non- ionizing techniques.
Methodology: Peripheral blood mononuclear cell (PBMC) cultures were performed to study osteoclastogenesis, in the
presence or absence of recombinant human monocyte-colony stimulating factor (M-CSF) and receptor activator of NFkB
ligand (RANKL). Flow cytometry was utilized to analyze osteoclast precursors (OCPs) and T cell phenotype. Tumour necrosis
factor a (TNF-a), RANKL and osteoprotegerin (OPG) were quantified in cell culture supernatants by ELISA. The effects of
RANKFc and anti-TNF-a antibodies were also investigated to determine their ability to inhibit osteoclastogenesis. In
addition, bone conditions and phenylalanine levels in PKU patients were clinically evaluated.
Principal Findings: Several in vitro studies in PKU patients’ cells identified a potential mechanism of bone formation
inhibition commonly associated with this disorder. First, PKU patients disclosed an increased osteoclastogenesis compared
to healthy controls, both in unstimulated and M-CSF/RANKL stimulated PBMC cultures. OCPs and the measured RANKL/OPG
ratio were higher in PKU patients compared to healthy controls. The addition of specific antagonist RANKFc caused
osteoclastogenesis inhibition, whereas anti-TNF-a failed to have this effect. Among PBMCs isolated from PKU patients,
activated T cells, expressing CD69, CD25 and RANKL were identified. Confirmatory in vivo studies support this proposed
model. These in vivo studies included the analysis of osteoclastogenesis in PKU patients, which demonstrated an inverse
relation to bone condition assessed by phalangeal Quantitative Ultrasound (QUS). This was also directly related to non-
compliance to therapeutic diet reflected by hyperphenylalaninemia.
Conclusions: Our results indicate that PKU spontaneous osteoclastogenesis depends on the circulating OCP increase and
the activation of T cells. Osteoclastogenesis correlates with clinical parameters, suggesting its value as a diagnostic tool for
an early assessment of an increased bone resorption in PKU patients.
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Introduction
Phenylketonuria (PKU; OMIM 261600) is an inborn error of
amino acid metabolism resulting from deficiency of phenylalanine
hydroxylase, the key enzyme for phenylalanine metabolism [1].
An early protein-restricted diet integrated with phenylalanine free
medical foods successfully prevents the irreversible developmental
delay characteristic of the natural course of the disease, by
maintaining plasma phenylalanine concentrations in non-neuro-
toxic range [2]. Despite the recommendation of life-long
adherence to treatment, poor compliance to dietary prescriptions
is common during adolescence [3], as the risk of mental
retardation due to hyperphenylalaninemia was historically thought
to be insignificant at this age. However, this laxity of dietary
restriction, has been related to systemic complications of PKU in
adulthood, as extensively reported recently [4]. Among these
complications, bone impairment of uncertain etiology has been
widely documented, using both radiological and ultrasound
methods [5–9] and it is typically associated with increasing age.
Bone is a highly dynamic tissue undergoing continuous
remodelling, with a fine equilibrium between bone formation by
osteoblasts and resorption by osteoclasts (OCs) [10]. The relative
preponderance of OC activity has recently been implicated in the
pathogenesis of bone impairment in some conditions [11], leading
to a growing interest towards OC biology and osteoclastogenesis
[12–15]. Circulating OC precursors (OCPs) have been reported in
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main cytokines involved in the regulation of OC differentiation
and function have been defined: macrophage colony stimulating
factor (M-CSF) induces the proliferation and differentiation of
OCPs; receptor activator of nuclear factor kB ligand (RANKL)
promotes OC activity and decreases their apoptosis [19];
osteoprotegerin (OPG) is the RANKL neutralizing soluble decoy
receptor [20]. An important link between immune system and
bone has been established, with OCPs requirement of activated T
cells to differentiate into OCs in vitro, in unstimulated conditions
[13,21,22]. Our group previously demonstrated an increased
spontaneous osteoclastogenesis in a small cohort of PKU patients
[23], consistent with the increased bone resorption markers in
affected patients [24]. In this study, we further investigated
osteoclastogenesis in PKU, considering its potential causes and
links with immune system; taking into account the individual bone
condition assessed by phalangeal Quantitative Ultrasound (QUS).
Results
Osteoclastogenesis in PBMC cultures from PKU patients
Numerous large tartrate-resistant acid phosphatase (TRAP)
positive and multinucleated OCs were identified in the unstimu-
lated PBMC cultures from PKU patients (OC average number/
well 149680; Fig. 1A), whereas few OCs appeared in the
unstimulated PBMC cultures from healthy controls (OC average
number/well 91651; Fig. 1B). After M-CSF and RANKL
addition to the cultures, osteoclastogenesis increased in the PKU
patients (OC average number/well 189697; Fig. 1C) and in
healthy controls (OC average number/well 124667, p,0.05;
Fig. 1D). The osteoclastogenesis in PKU patients was significantly
higher than in healthy controls, in unstimulated and stimulated
cultures, p,0.01 (Fig 1E). OCs of PKU patients were then
characterized for the expression of vitronectin receptor, a typical
OC marker (Fig. 1F). PKU osteoclastogenesis depends on T cells,
as in T cell-depleted cultures OCs did not differentiate without
exogenous factors (data not shown). The bone resorbing activity
was higher in unstimulated PKU patients’ cultures than in healthy
controls (Fig. S1).
Circulating OCPs are increased in PKU patients
Based on CD16 expression and monocyte classification criteria
set previously published [25], human CD14+ monocytes can be
divided in two subsets CD16- and CD16+. CD14+ CD16+ can
differentiate into OCs [26], and are classified as OCPs. In
monocyte population, the number of CD14+ CD16+ OCPs was
higher in PKU patients (7.260.5%, Fig. 2A) than in healthy
controls (2.761.1%, Fig. 2B). Analysis of the expression of specific
OCP markers on CD14+ cells showed higher co-expression of
CD11b and CD51/61 in PKU patients (74.2616.9%, Fig. 2C)
compared to healthy controls (7.563.2%, Fig. 2D). CD51/61
expression was higher on CD16+ cells from PKU patients
(4.861.4%, Fig. 2E) than healthy controls (0.460.6%, Fig. 2F).
Spontaneous osteoclastogenesis is mediated by RANKL
In order to identify molecules promoting osteoclastogenesis in
cultures, we dosed TNF- a, RANKL and OPG in supernatants, at
day 5 and 10 of culture. At day 5, TNF-a levels were higher than
at day 10 and its concentration increased dramatically in patients’
cultures compared to healthy controls (Fig. 3A, p,0.001). At day
10, RANKL release resulted significantly increased in PKU
patients compared to healthy controls (Fig. 3B, p,0.001). OPG
levels in PKU patients and healthy controls were not significantly
different (Fig 3C). However, the RANKL/OPG ratio was
significantly higher in PKU patients than in healthy controls
(Fig. 3D, p,0.01), explaining the presence of spontaneous
osteoclastogenesis in unstimulated cultures of PKU patients.
To define the main molecules that promote osteoclastogenesis,
we added RANKFc and anti-TNF-a at different concentrations to
patientPBMC cultures. A marked and significant osteoclastogenesis
inhibition was detected by RANKFc compared to unstimulated
PBMC cultures, where OCs spontaneously differentiate (Fig. 4A,
p,0.01). Anti-TNF-a failed to significantly reduce osteoclastogen-
esis compared to the unstimulated condition (Fig. 4B).
PKU patients show an increase number of circulating
activated T cells
T cell phenotype from PKU patients were analyzed to investigate
their possible involvement in promoting osteoclastogenesis, as
described in many diseases characterized by bone loss. Other than
expressing RANKL (data not shown), we found that T cells also
expressed CD69 and CD25, two typical activation markers. CD4+
cells were significantly reduced in PKU patients compared to
healthy controls (67.367.1% and 87.6610.2%, respectively,
p,0.01). 3.7%61.1 of CD4+ cells, expressed both CD69 and
CD25 in PKU patients (Fig. 5A), whereas healthy control CD4+
cells did not co-express the two markers (Fig. 5B). CD8+ cells were
comparable in patients and controls (27.5611.9% and 3165.3%,
respectively). The number of activated T cells was directly
correlated with osteoclastogenesis (r=0.483, p,0.001), and in-
versely correlated to QUS parameters (AD-SoS SDS: r=20.210,
p,0.05; BTT SDS: r=20.292, p,0.05).
Spontaneous osteoclastogenesis correlates with clinical
PKU parameters
In PKU patients, spontaneous osteoclastogenesis was directly
correlated with both age (r=0.386, p=0.03) and blood phenylal-
anine concentration (r=0.458, p=0.01), and these correlations
were not observed in healthy controls (Fig. 6A). Moreover, PKU
patients displayed a significant negative correlation between QUS
parameters and spontaneous osteoclastogenesis (Amplitude-Depen-
dent Speed of Sound, AD-SoS SDS: r=20.553, p,0.001; Bone
Transmission Time, BTT SDS: r=20.631, p,0.001) (Fig. 6B).
QUS assessment in PKU patients revealed an overall normal
bone condition comparable to healthy population (AD-
SoS SDS=0.0261.51, p=0.946; BTT SDS=20.1361.35;
p=0.550). Fourteen patients (35%, mean age 22.466.6 years)
had abnormal bone scans, with a reduction of both parameters
with respect to normal population (AD-SoS SDS =21.6160.97,
p,0.001; BTT SDS =21.6060.98; p,0.001). The 22 patients
aged ,15 years (mean age 8.763.6 years) showed increased AD-
SoS and BTT with respect to normal population (AD-SoS SDS
=0.8861.03, p,0.001; BTT SDS =0.6260.93; p,0.001).
Similarly, bone impairment was also observed in the 18 patients
aged .15 years, (AD-SoS SDS =21.0461.34 and BTT SDS
=21.0461.24; both parameters, p,0.001). In patients with blood
phenylalanine level steadily lower than 10 mg/dl (n=24, mean
age 10.867.8 years), AD-SoS and BTT SDS were significantly
higher than controls (0.9360.92 and 0.6260.78, respectively,
p,0.001), whereas reduced QUS parameters were observed in
patients with phenylalanine concentration .10 mg/dl (n=16,
mean age 20.364.5 years, AD-SoS SDS =21.3561.16,
p,0.001; BTT SDS =21.2661.26; p,0.001). In addition
QUS parameters were negatively correlated with both patients’
age (AD-SoS SDS: r=20.736, p,0.001; BTT SDS: r=20.726,
p,0.001) and mean blood phenylalanine concentration (AD-SoS
SDS: r=20.788, p,0.001; BTT SDS: r=20.807, p,0.001).
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In the field of biochemical genetics, there has been a growing
interest towards adult complications of PKU [4]. In particular, age
relatedbone impairment has been widely reported in PKU patients,
mainly by using radiological methods (5–8). To date, the ‘‘gold
standard’’ for bone assessment in childhood is still debated [27].
Currently dual x ray absorptiometry (DXA) remains the most
commonly employed method for bone assessment. However, this
technique may present some limitations when applied in the
pediatric age group. In addition to the repeated radiological
exposure to adolescents, DXA provides a selective estimation of
Figure 1. Osteoclastogenesis in PKU patients and healthy controls. Numerous, multinucleated (,3 nuclei/cell), TRAP+ OCs (black arrows)
were obtained from unstimulated PBMCs of PKU patients (A), while few OCs were observed in healthy control cultures (B). After addition of M-CSF and
RANKL, a significant increase in osteoclastogenesis was observed both in PKU patient and in healthy control PBMC cultures (C, D, respectively). The OC
numberinPBMCcultureswasquantified,resultinghigherinPKUpatientsthaninhealthycontrols(E).OCswerenormallydistributed,hencePKUpatients
and healthy controls were compared by means of unpaired T-test. OCs from PKU patients’ PBMC cultures expressed vitronectin receptor (F).
doi:10.1371/journal.pone.0014167.g001
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measurement dependent on the bone surface area; a finding largely
influenced by the physiological modifications of bone geometry
occurring during growth [28]. Consequently, QUS methods have
been increasingly utilized for bone assessment at different ages,
including young patients [9]. These techniques are based on the
principle that ultrasound is differently modified in its shape,
intensity, and speed on the basis of structural properties of bone
[29]. QUS also provides additional information compared to DXA,
such as cortical thickness, porosity, elasticity, and anisotropy [30–
32]. Prior reports have demonstrated the strict correlation of
phalangeal to the gold standard bone mineral density measurement
by DXA. In particular, significant correlation between both spine-
and total body-bone mineral density assessed by DXA and
phalangeal QUS has been reported (r=0.45 p,0.05 and
r=0.56, p,0.01, respectively) [33]. Moreover, phalangeal QUS
is particularly suitable for bone evaluation in pediatrics, as it is easy
and rapid to use, non-invasive, inexpensive, and radiation-free [34].
Whatever the method employed for bone assessment, the
relationship among the bone impairment, the effects of early
protein restriction, and the commonly observed late dietary
discontinuation with consequent chronic hyperphenilalaninemia is
not completely clarified [23]. However, a pathogenic role of chronic
exposure to high blood phenylalanine concentration on the bone
compartment has been described in animal models [26]. Bone
impairment in PKU seems to reflect the relative preponderance of
OC activity, with disruption of the physiological homeostatic
equilibrium between bone formation and resorption [35]. Consid-
ering the central role of OCs in the pathogenesis of diseases
characterized by increased bone resorption, the investigation of
osteoclastogenesis from PBMCs may be a promising approach to
understand the mechanism of bone loss in several conditions, as
recently outlined in different diseases, including PKU [11,17,23].
A prior study from our group [23], reported a higher incidence
of spontaneous osteoclastogenesis (PBMCs differentiating into
OCs without exogenous factors) in a large cohort of PKU patients
compared to healthy controls. Additionally, we previously
reported that supplementation of M-CSF and RANKL led to an
increase of osteoclastogenesis in PKU patients and in healthy
controls, indicative of a physiological response to stimulation. This
work aimed to expand on that study by investigating the causes of
the osteoclastogenesis. This was performed by studying the
presence of an abnormal number of circulating OCPs, since one
cause of spontaneous osteoclastogenesis in different pathological
conditions characterized by bone loss is represented by their
increase [36]. First the number of OCPs expressing CD14/CD51-
61/CD11b and a particular OCP subset, expressing CD14 and
CD16, were elevated in PKU. This subset of OCPs expressing
CD14 and CD16 was previously described in inflammatory
diseases characterized by loss of bone mass, such as psoriatic
arthritis [25]. In order to identify the molecules responsible for
osteoclastogenesis in unstimulated PBMC cultures from PKU, we
measured the TNF-a, RANKL and OPG concentrations in
supernatants at different time points. TNF-a concentrations were
higher in cultures from PKU patients than in healthy controls.
Intersestingly, TNF-a levels were particularly high at the
beginning of the culture, suggesting a TNF-a involvement in
promoting OCPs, which self-regulate TNF-a release. In fact,
CD14+CD16+ OCPs are a major source of TNF-a [37] and
CD16 regulates both the TNF-a activation and inhibition. We
Figure 2. Circulating OCPs are increase in peripheral blood of PKU patients. Representative dot plots of CD14+CD16+ OCPs (A, B). The
analysis of the expression of OCPs markers on CD14+ cells show CD11b+CD51/61+ (C, D) and CD16+CD51/61+ (E, F) increase in PKU compared to
controls.
doi:10.1371/journal.pone.0014167.g002
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be due to CD16 regulation, where CD16 increases and then
inhibits the TNF-a release. The RANKL to OPG ratio was higher
in PKU patients than in healthy controls, suggesting the role of
RANKL as major promoter of the osteoclastogenesis in PKU
patients. To confirm this result, we showed OC inhibition after
RANKFc addition to unstimulated PKU cultures. On the
contrary, we did not observe any osteoclastogenesis modulation
after addition of the anti-TNF-a antibody, confirming our
hypothesis that TNF-a acts on OCPs. The osteoclastogenesis
dependence on T cells has been widely demonstrated in many
diseases characterized by increase bone resorption activity [22,38–
40]. In this study we identified such a mechanism in PKU
osteoclastogenesis, by the lack of OC differentiation in T cell-
depleted culture, without addition of exogenous factors. This result
is in accordance to prior findings and can be explained by
RANKL expression on T cells. The number of CD4+ T cells in
PKU patients was reduced compared to healthy controls.
However PKU patient CD4+ T cells expressed CD69 and
CD25, typical activation markers. Moreover, the number of
activated CD4+ T cells directly correlated with osteoclastogenesis,
confirming the role of T cells in promoting OC differentiation.
These data highlight a peculiar condition of immune system in
PKU patients, which needs further investigations for its potential
clinical relevance. Even though our group previously reported the
presence of spontaneous osteoclastogenesis in PKU patients, this
work describe a novel link between osteoclastogenesis and the
immune system in the pathogenesis of bone impairment in PKU.
Osteoclastogenesis and the number of activated T cells in PKU
patients were inversely related to bone condition. This finding
suggests a possible relationship among spontaneous osteoclasto-
genesis, immune system and bone damage, as previously described
in different diseases by our group and others [16,18,36]. In
addition to the confirmation of the previously reported correlation
between QUS parameters and metabolic control in PKU [9], a
direct connection between plasma phenylalanine concentration
Figure 3. Osteoclastogenic cytokines in culture media. Box and whisker plots showed cytokines dosed in the PBMCs supernatants. Each Box
represents the 25
th to 75
th percentiles. Lines outside the boxes represent the minimum and maximum values. Lines inside the boxes represent the
medians calculated for all the data set. The p value indicated was calculated with the Mann-Whitney U test after correction for age. In PKU patients
TNF-a was higher than in healthy controls (A). RANKL resulted significantly higher in PKU than in controls at day 10 (B), whereas OPG did not differ
between patients and controls (C). The RANKL to OPG ratio was in favour of RANKL in PKU patients compared to healthy controls (D).
doi:10.1371/journal.pone.0014167.g003
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with a possible role of hyperphenylalaninemia in enhancing OC
differentiation and consequently promoting bone resorption.
In conclusion, PKU patients showed increased osteoclastogenesis
compared to healthy controls, depending on an OCP increased
number. RANKL regulates PKU osteoclastogenesis, whereas TNF-
a seems to stimulate and be regulated by OCPs. The osteoclasto-
genesis and T cell activation state correlates with PKU patients’
bone condition. Thus, the finding of a specific sub-population of
activated T cells accounting for spontaneous osteoclastogenesis
infers a dysfunctional immune system activation in PKU patients.
We believe that the immune system in PKU patients needs to be
deeply investigated for its potential clinical relevance.
Materials and Methods
Subjects
The study was approved by the Ethical Committee of Children
Hospital Regina Margherita- S.Anna. Written informed consent
was obtained from all subjects or from their parents when under
age. Forty patients affected by PKU (18 males and 22 females,
mean age 14.668.1 years) and 40 age- and sex-matched healthy
controls were enrolled in this study. Height and pubertal
development were assessed according to Tanner’s standards and
criteria. BMI was calculated using the weight/height
2 (Kg/m
2)
formula, corrected for sex and age, and expressed as BMI SDS,
according to Italian reference charts [41]. Exclusion criteria were
the following: short stature (defined as height below -2 standard
deviation for age), history of immobility or high physical activity,
treatment with drugs interacting with bone metabolism (including
calcium and vitamin D supplementations), sub-optimal nutrition
(defined as dietary restriction with caloric intake less than 70% of
recommended values for age or loss of more than 10% of body
weight during the last year) and concomitant diseases with bone or
blood involvement. Clinical features of patients and controls are
detailed in table 1. PKU patients were treated with a protein-
Figure 4. PKU osteoclastogenesis is RANKL-dependent. The
RANKFc addition to unstimulated PBMC culture from PKU patients
caused a dose-dependent inhibition of OC formation (A), whereas anti-
TNF-a failed to inhibit osteoclastogenesis (B). The p value indicated was
calculated by unpaired T-test.
doi:10.1371/journal.pone.0014167.g004
Figure 5. PKU patients have activated T cells in peripheral
blood. Representative dot plots of CD4+ T cells expressing both CD69
and CD25 in PKU patient (A) and healthy controls (B).
doi:10.1371/journal.pone.0014167.g005
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amino acid mixture in three portions during the day, warranting
the daily recommended age-related intakes of macronutrients,
minerals and vitamins [42]. For each patient, monthly plasma
phenylalanine levels were collected in the year prior to the study.
Healthy subjects enrolled as controls had a normo-caloric free diet,
meeting the daily age-related recommendations [43].
Cell cultures
PBMCs were obtained from peripheral blood samples according
to the Ficoll method, as previously described [18]. For all patients
and controls PBMCs were plated in 24-well plates (2610
6 cells/
well), using alpha-minimal essential medium (a-MEM, supplied by
Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine
serum, benzylpenicillin (100 IU/ml)and streptomycin (100 mg/ml)
Figure 6. PKU osteoclastogenesis correlates with clinical parameters. Spontaneous osteoclastogenesis in PKU patients shows a significant
correlationwithage (N, continuous line)andbloodphenylalanine concentration, dosed in the last year before the study (#, dotted line). PKU patientsshowed a
significant negative correlation between spontaneous osteoclastogenesis and bone condition assessed by QUS parameters, Amplitude-Dependent Speed of
Sound (AD-SoS) (#, dotted line) and Bone Transmission Time (BTT) (N, continuous line). Correlations were evaluated by Pearson’s coefficients.
doi:10.1371/journal.pone.0014167.g006
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humidified atmosphere of 5% CO2. To obtain fully differentiated
human OCs, PBMCs were cultured in presence or absence of
recombinant human M-CSF (25 ng/ml) and RANKL (30 ng/ml),
for15days.In7 independentexperiments,PBMCswerecultured in
96-well plates (5610
5 cells/well) in the presence of increasing
concentration of RANKFc (30–50 ng/ml) and anti-TNF-a (1,5–3–
5 mg/ml) (supplied by PeproTech, London, UK). At the end of the
culture period, cells were stained for tartrate-resistant acid
phosphatase (TRAP, kit supplied by Sigma-Aldrich, St Louis,
MO) and vitronectin receptor (Chemicon International, Temecula,
CA). OCs were identified as TRAP positive, multinucleated cells,
containing three or more nuclei. The T cell depletion was
performed according to a previously published method [35]. To
study OC resorbing activity, PBMCs from 5 patients and 5 healthy
controls were plated on BioCoat osteologic bone cell culture system
(5610
5 cells/well) provided by BD Biosciences (Bedford, MA) and
cultured for 20 days. In order to visualize pits formed by OCs, the
cells were removed by washing each well with NaOCl and
resorption lacunae were identified by light microscopy. The
quantification of resorbing area was perfomed by a semi-automated
image analyzing system [44].
Flow cytometry
To identify OCPs, aliquots of 1610
6 PBMC from 15 patients 15
controls were incubated with the following anti-human antibodies:
APC-conjugated CD11b, PE-conjugated CD51/61 (BD Pharmin-
gen, San Diego, CA), FITC-conjugated CD14 (Chemicon
International, Temecula, CA) and PerCP-conjugated CD16
(Biolegend, San Diego, CA). To investigate the phenotype of T
cells, PBMCs were stained with the following anti-human
antibodies: APC-conjugated CD4, FITC-conjugated CD25 (Cal-
tag, Burlingame, CA), PE-conjugated CD69 (Biolegend, San
Diego, CA) and related isotype controls. The expression of
RANKL by T cells was assessed by indirect staining using a
monoclonal mouse anti-RANKL (Santa Cruz Biotechology, Santa
Cruz, CA) as primary antibody and a goat anti-mouse FITC-IgG1
(SouthernBiotech, Birmingham, AL). Appropriate controls were
used to determine optimal voltage settings and electronic
subtraction for the spectral fluorescence overlap correction.
Samples were analyzed in a FACsCalibur instrument (Becton
Dickinson, Bedford, MA) and elaborated by Flowjo (Treestar,
Ashland, OR).
ELISA (Enzyme-Linked Immunosorbent Assay)
Supernatants from cultures not supplemented with growth
factors were collected at day 5 and 10 (when medium was
refreshed), and the concentrations of TNF-a (Quantikine; R&D
Systems, Minneapolis, MN), RANKL (Biomedica; Biomedica
Medizinprodukte GmbH and Co. KGA) and OPG (BenderMed-
Systems, Vienna, Austria) were measured by commercially
available ELISA kit, according to manufacturer’s instructions.
The absorbance was determined by an ELISA reader at 450 nm
and the results were expressed as mean 6 SD.
Assessment of bone condition
All patients underwent a phalangeal QUS measurement using
the DBM Sonic-Bone Profiler (Igea, Carpi, Modena, Italy). The
device consists of an electronic calliper with emitter and receiver
probes recording ultrasound beam modifications through the
phalanx. Acoustic coupling was achieved through standard
ultrasound gel. Amplitude-Dependent Speed of Sound (AD-SoS)
was measured in m/s, considering the first received signal with
amplitude of 2 mV. AD-SoS is primarily related to the bone
density [45] and low AD-SoS is associated with a reduced bone
mineral density assessed by DXA. This parameter is influenced by
the thickness of the surrounding soft tissues at proximal phalanges
of the hand. Bone Transmission Time (BTT) was calculated in ms
by subtracting the instant corresponding to the arrival time of the
fastest signal from the time of transmission of a pulse at 1700 m/s
velocity, being independent of soft-tissue thickness [46,47]. BTT is
closely related to cortical width and can discriminate different
bone disease patterns independent of bone density [30].
All measurements were performed by the same trained operator
at the distal metaphyses of the proximal phalanges of fingers II-V
of dominant hand.
AD-SoS and BTT values were compared to sex- and age-
matched healthy controls [47] and expressed as SDS. Short-term
precision was assessed based on 100 measurements repeated on 20
healthy subjects aged 3–18 years measured 5 times each, disclosing
intra-operator coefficients of variation of 0.72% and 1.07% for
AD-SoS and BTT, respectively.
Statistical analysis
The normal distributions of each parameter were determined
by Kurtosis’s test. Since none of the cytokines analyzed were
normally distributed, TNF-a, RANKL and OPG were compared
by means of the Mann-Whitney U test after weight for age. The
other parameters showed a normal distribution and they were
compared by Student’s unpaired T test. Pearson’s correlation
coefficients were used to check univariate associations. The SPSS
17.0 software package was used to process the data with p,0.05 as
the significance cut-off.
Supporting Information
Figure S1 Bone resorption assay. Numerous resorption lacunae
were observed in PKU patients compared to healthy controls (A,
B, respectively). Bone resorbing activity resulted higher in PKU
than in control (C). Magnification 20X.
Found at: doi:10.1371/journal.pone.0014167.s001 (0.16 MB TIF)
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Table 1. Clinical features of patients with phenylketonuria
(PKU) compared to healthy controls.
CHARACTERISTICS PKU CONTROLS p
Number 40 40 -
Gender (Male/Female) 18/22 18/22 -
Age (years) 14.668.1 12.266.3 0.15
Height (cm) 141.9625.9 141.2625.4 0.09
BMI SDS 20.0161.14 0.1260.66 0.45
Blood phenylalanine
(mg/dl)
9.865.8 0.960.3 ,0.01
doi:10.1371/journal.pone.0014167.t001
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